abstract |
The present invention relates to indazolyl (1;2,4) triazine compounds having the general structure of Formula (I); useful as protein kinase inhibitors, pharmaceutical compositions comprising such compounds, and methods of treatment using the compounds and compositions to treat conditions such as cancer and proliferative diseases or immunodeficiencies, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease. The substituents are defined in the claims. |